Predictive Biomarker Impact Factor

Impact Factor is an indicator of the number of citations within the scientific journals of clinical and medical category. Impact factor is measured based on the frequency with which a journal's articles are cited in scientific publications, is a putative marker of journal quality. Publication ccitation, index of researchers, and journal impact factors are used to measure the impact & importance of research. Journal Impact factor are most widely used metric for measuring the quality of clinical Journal. Immunomodulatory drugs (IMiDs) are highly active in the treatment of hematological malignancies, including multiple myeloma (MM), non-Hodgkin lymphoma and chronic lymphocytic leukaemia, but the mechanisms of action are still incompletely understood. Although several mechanisms have been proposed to explain the activity of these drugs in multiple myeloma (MM), the precise cellular targets and molecular mechanisms have only recently become clear. Cereblon (CRBN) a member of the cullin 4 ring ligase complex (CRL4) has been identified as the primary target of thalidomide teratogenicity and moreover, as an essential requirement for response to IMiD therapy. Cereblon's central role as a target of lenalidomide and pomalidomide suggests potential utility as a predictive biomarker of response or resistance to IMiD therapy; Low CRBN expression was found to correlate with poor drug response in MM cell lines and primary MM. Expression of CRBN protein in myeloma cells assessed using immunohistochemistry is a practical approach to predict the response of IMiDs in MM patients. CRBN expression is therefore a potential predictive biomarker for response and survival in MM, decreases expression developed resistance to IMiDs. The discovery of cereblon as a target of thalidomide and the IMiDs has enabled a pursuit of better understanding of the molecular mechanism of action by these agents. In parallel, there is significant clinical interest to investigate the possible role of cereblon as a biomarker for the IMiD compounds response or resistance. (Adel Gouri , AmelBouacha, AouliaDekaken, FaizaMehiddine, Ahmed AimenBentorki, AminaYakhlef and Mehdi Beleilli, Cereblon as a Predictive Biomarker for Imid Therapy Sensitivity)

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024